Department of Surgery, College of Medicine, East Tennessee State University, Johnson City, Tennessee.
Wounds. 2021 Oct;33(10):245-252.
For persons with diabetes, surgery is fraught with complications; of primary concern is postoperative infection. A postoperative infection rate of up to 13% has been noted in patients with diabetes undergoing elective surgical procedures compared with less than 3% in nondiabetic populations.
The objective of this study was to provide preliminary evaluation of the efficacy of a novel bioresorbable microfilm matrix (20 µm thick) containing very low amounts of silver (0.16 mg/in²) in preventing surgical site infections when placed at the level of subcutaneous tissue and dermis prior to primary closure in the patient with diabetes undergoing elective surgery.
Twenty-two patients with diabetes undergoing nonemergent or elective foot or ankle surgery and who met at least 1 of the following 6 criteria were included in the study: neuropathy, infection, open wound, history of recurrent infection, nonhealing wound, or peripheral vascular disease. Patients underwent amputation, removal of exostosis, midfoot bone removal, Achilles tendon repair, bunionectomy, or an elevating osteotomy with primary closure of the wound. After hemostasis was obtained and subcutaneous closure achieved, if applicable, the bioresorbable microfilm matrix was applied just deep to the incision at the level of subcutaneous tissue and dermis, and the incision primarily closed. A nonadherent cover dressing was applied over the suture line, and routine follow-up was scheduled for 3 to 5 days later.
No patient exhibited signs of infection at initial follow-up, and all adherent patients achieved complete healing during the 3-month follow-up period. Eighteen patients healed at a rate typical for the respective procedure. In 2 patients, time to healing was delayed secondary to weight-bearing dehiscence. Two patients were not included in the results secondary to multiple infractions of nonadherence with the postoperative protocol.
The application of microfilm matrix in surgical incisions at the level of subcutaneous tissue and dermis prior to primary closure is safe for and has the potential to prevent postoperative surgical site infections in at-risk patients with diabetes..
对于糖尿病患者来说,手术充满了并发症;主要关注的是术后感染。与非糖尿病患者相比,接受择期手术的糖尿病患者术后感染率高达 13%,而后者不到 3%。
本研究旨在初步评估一种新型生物可吸收微孔膜基质(厚 20 µm)的疗效,该基质含有极少量的银(0.16mg/in²),可在糖尿病患者接受择期手术时,在皮下组织和真皮水平放置于切口处,然后进行一期闭合,从而预防手术部位感染。
本研究纳入了 22 名患有糖尿病且符合以下至少 1 项标准的患者:神经病变、感染、开放性伤口、复发性感染史、伤口不愈合或外周血管疾病。患者接受了截肢、骨赘切除、中足骨切除、跟腱修复、拇囊炎切除术或抬高截骨术,并进行一期闭合。止血并完成皮下闭合后,如果适用,将生物可吸收微孔膜基质应用于切口的皮下组织和真皮水平,然后一期闭合切口。在缝合线上应用非粘性覆盖敷料,并在术后 3 至 5 天进行常规随访。
初始随访时,没有患者出现感染迹象,所有可粘附的患者在 3 个月的随访期间均完全愈合。18 名患者的愈合速度符合各自手术的典型速度。有 2 名患者因负重性切口裂开而愈合时间延迟。有 2 名患者因多次违反术后方案而未纳入结果。
在进行一期闭合之前,将微孔膜基质应用于皮下组织和真皮水平的手术切口,对于糖尿病高危患者来说是安全的,并且有可能预防术后手术部位感染。